Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial
  1. Home
  2. Publications
  3. Supplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial

Supplementary Table S2 from Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial

Authors:
  • ASAbdulazeez Salawu
    Abdulazeez Salawu
  • BWBen X. Wang
    Ben X. Wang
  • MHMing Han
    Ming Han
  • CGCaryn Geady
    Caryn Geady
  • AHAlya Heirali
    Alya Heirali
  • HBHal K. Berman
    Hal K. Berman
  • TPThomas D. Pfister
    Thomas D. Pfister
  • AHAlberto Hernando-Calvo
    Alberto Hernando-Calvo
  • EAEsmail Mutahar. Al-Ezzi
    Esmail Mutahar. Al-Ezzi
  • LSLee-Anne Stayner
    Lee-Anne Stayner
  • AGAbha A. Gupta
    Abha A. Gupta
  • OAOlubukola Ayodele
    Olubukola Ayodele

Open Access
Publisher website
Google Scholar
  • 16 September 2024
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.27034225
Abstract
Table S2: Best overall responses (iRECIST) of leiomyosarcoma patients on the DAPPER study
Keywords
  • BIOLOGICAL AGENTS & THERAPIES
  • BIOMARKERS
  • IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
  • SARCOMAS
  • SOFT-TISSUE SARCOMA
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.